Efficiacy and safety of the long-term application of combined chondroprotector for treatment of osteoarthrosis of knee joints: open prospective randomized trial


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. Evaluation of the safety and efficacy of the combined chondroprotector (chondroitin sulfate+glucosamine hydrochloride) in patients suffering from osteoarthrosis in combination with arterial hypertension (AH). Methods. The results of a 24-week treatment with CCP of patients with osteoarthrosis of knee I-III radiographic stages are presented. The CCP tablets contained 500 mg of chondroitin sodium sulfate and 500 mg of glucosamine hydrochloride. The study included 44 patients with osteoarthrosis aged 42.7±6.6 years (13 men, 31 women). Patients are divided into two comparable groups: Group 1 - with isolated osteoarthrosis, the Group 2 - with osteoarthrosis in combination with AH. The effectiveness of the drug was assessed by visual analogue scale (VAS), WOMAC index, and patients’ needs for non-steroidal anti-inflammatory drugs (NSAIDs). Results. As a result of treatment, the efficacy of the drug was de-monstrated in both groups of patients. A significant reduction in the pain syndrome according VAS has been achieved; an improvement in the mean WOMAC score for all indicators: a reduction in morning stiffness; reduction of functional insufficiency; and overall index the total indicator, was observed. Conclusion. CCP studied has shown a good therapeutical effect in osteoarthrosis and in combination with AH. The positive therapeutic effect of CCP contributed to a reduction in the dosage of NSAIDs. The good tolerability of the drug is emphasized: with prolonged use of the drug, none of the patients discontinued participation in the study due to poor tole-rance or side effects.

Full Text

Restricted Access

About the authors

E. Yu Aleksenko

Chita State Medical Academy

Email: e-alexe@mail.ru
MD, Associate Professor, Prof. at the Department of Polyclinic Therapy with the Course of Medical Rehabilitation

A. V Govorin

Chita State Medical Academy

References

  1. Allen K.D., Golightly Y.M. State of the evidence. Curr. Opin. Rheumatol. 2015;27(3):276-83.
  2. Российские клинические рекомендации. Ревматология. Под ред. Е.Н. Насонова. М., 2017. С. 240-52.
  3. Rovati L.C., Girolami F., D'Amato M., Giacovelli G. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: Results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin. Arthritis Rheum. 2016;45: 34-41.
  4. Насонова В.А. Остеоартроз - проблема полиморбидности. Consilium medicum. 2009; 1:5-8.
  5. Мендель О.И., Наумов А.В., Верткин А.Л., Алексеева Л.И., Шамуилова М.М., Лучихина Л.В. Остеоартроз и сердечно-сосудистые заболевания у лиц пожилого возраста: клинические и патогенетические взаимосвязи. Успехи геронтологии. 2010;23(2):304-13.
  6. Caporali R., Cimmino M.A., Sarzi-Puttini P., Scarpa R., Parazzini F., Zaninelli A., Ciocci A., Montecucco C. Comorbid conditions in the AMICA study patients: effects on the quality of life and drug prescriptions by general practitioners and specialists. Semin. Arthritis Rheum. 2005;35:31-7.
  7. Findlay D.M. Vascular pathology and osteoarthritis. J. Rheumatol. 2007;46: 1763-68.
  8. Hochberg M.C. Mortality in osteoarthritis. Clin. Exp. Rheum. 2008;26:120-24.
  9. Верткин А.Л., Алексеева Л.И., Наумов А.В., Иванов В.С., Шамуилова М.М., Мендель О.И. Остеоартроз в практике врача-терапевта. РМЖ. 2008;7:476-81.
  10. Хитров Н.А. Современные пути лечения остеоартроза. РМЖ. 2009;21:1453-57.
  11. Храмцова Н.А. Кардиоваскулярные заболевания при патологии суставов и остеопорозе в Прибайкалье. Автореф. дисс. докт. мед. наук. Иркутск, 2010. 45 с.
  12. Ребров А.П., Харитонова И.А. Особенности суточного профиля артериального давления и показатели жесткости артерий у больных остеоартрозом при наличии и отсутствии артериальной гипертензии. Саратовский научномедицинский журнал. 2009;1(5):68-70.
  13. Pincus T., Sokka Т. Mortality in rheumatic diseases. Clin. Exp. Rheum. 2008;26:1-4.
  14. Katz J.D., Agrawal S., Velasquez M. Getting to the heart of the matter: osteoarthritis takes its place as part of the metabolic syndrome. Curr. Opin. Rheumatol. 2010;22:512-19.
  15. Hudson M., Rahme E., Richard H., Pilote L. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase-2 inhibitors: a class effect? Arthritis Rheum. 2007;57(3):516-23.
  16. Afonso V., Champy R., Mitrovic D., Collin P., Lomri A. Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine. 2007;74(4):324-29.
  17. Анкудинов А.С., Калягин А.Н. Иммуномодулирующие цитокины при хронической сердечной недостаточности, ассоциированной остеоартрозом коленных суставов. Сибирский медицинский журнал (Иркутск). 2015;6:109-12.
  18. Косарев В.В., Бабанов С.О. Эффективность современных хондропротекторов при остеоартрозе. Медицинский совет. 2014;5:92-9.
  19. Цветкова Е.С., Иониченок Н.Г., Денисов Л.Н. Современная фармакотерапия остеоартроза коленных суставов: особенности симптоматического и болезнь - модифицирующего действия. Сообщение 1. Особенности симптоматического действия современных препаратов при остеоартрозе коленных суставов. Научно-практическая ревматология. 2015; 53(1):63-8.
  20. Олюнин Ю.А. Обзор остеоартроза: современные принципы лечения и предпосылки для разработки персонифицированной терапии. Научно-практическая ревматология, 2016; 6 (54): 641-53.
  21. Singh J.A., Noorbaloochi S., MacDonald R., Maxwell L.J. Chondroitin for osteoarthritis. Cochrane Database Syst. Rev. 201;1:CD005614.
  22. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., Stitt L.W. Validation study of WOMAC. A health status instrument for measuring clinically impotant patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol. 1988;15:1833-40.
  23. Шкалы, тесты и опросники в медицинской реабилитации / Под ред. А.Н. Беловой, О.Н. Щепетовой. М.: Антидор, 2002. С. 205-24.
  24. Clegg D.O., Reda J.D., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., Bradley J.D., Bingham C.O. 3rd, Weisman M.H., Jackson C.G., Lane N.E., Cush J.J., Moreland L.W., Schumacher H.R. Jr, Oddis C.V., Wolfe F., Molitor J.A., Yocum D.E., Schnitzer T.J., Fürst D.E., Sawitzke A.D., Shi H., Brandt K.D., Moskowitz R.W., Williams H.J. Glucosamine, Chondroitin sulfate, and two in combination for painful knee Osteoarthritis. N. Engl. J. Med. 2006;354: 795-808.
  25. Davies-Tuck Ml., Hanna F, Davis S.R., Bell R.J., Davison S.L., Wiuka A.E., Adams J., Cicuttini F.M. Total cholesterol and triglycerides are associated with the development of new bone marrow lesions in asymptomatic middle-aged women -a prospective cohort study. Arthritis Res. Ther. 2009;11:181.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies